Premium
A Metallo Pro‐Drug to Target Cu II in the Context of Alzheimer's Disease
Author(s) -
ConteDaban Amandine,
Ambike Vinita,
Guillot Régis,
Delsuc Nicolas,
Policar Clotilde,
Hureau Christelle
Publication year - 2018
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201706049
Subject(s) - oxidative stress , reactive oxygen species , superoxide dismutase , context (archaeology) , chemistry , drug , amyloid (mycology) , ligand (biochemistry) , peptide , biochemistry , pharmacology , biophysics , biology , receptor , inorganic chemistry , paleontology
Alzheimer's disease and oxidative stress are connected. In the present communication, we report the use of a Mn II ‐based superoxide dismutase (SOD) mimic ([Mn II (L)] + , 1 + ) as a pro‐drug candidate to target Cu II ‐associated events, namely, Cu II ‐induced formation of reactive oxygen species (ROS) and modulation of the amyloid‐β (Aβ) peptide aggregation. Complex 1 + is able to remove Cu II from Aβ, stop ROS and prevent alteration of Aβ aggregation as would do the corresponding free ligand LH. Using 1 + instead of LH in further biological applications would have the double advantage to avoid the cell toxicity of LH and to benefit from its proved SOD‐like activity.